Commenting on the findings, Prof Robert Pirker,
programme director for lung cancer at the Vienna General Hospital in Vienna, Austria, not involved in the
study, said: «This subgroup analysis shows that the effect of necitumumab was slightly greater in patients with EGFR
expressing tumours than it was in the entire SQUIRE population.